Establishment Labs (NASDAQ:ESTA) Stock Crosses Above Fifty Day Moving Average – Here’s Why

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $67.38 and traded as high as $70.53. Establishment Labs shares last traded at $68.97, with a volume of 790,787 shares.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Third-quarter revenue increased 33.9% year over year to approximately $72.0 million, exceeding analysts’ expectations of $66.8 million. U.S. revenue more than doubled to $26.0 million, while international revenue rose 9.7%. Establishment Labs Q3 Revenue Rises 33.9% to $72.0 Million
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $274 million and projected roughly 25% revenue growth for 2027, signaling continued confidence in demand and commercial execution. Establishment Labs Projects 25% Revenue Growth in 2027
• Positive Sentiment: The company reported its first quarter of positive operating and free cash flow, including approximately $7.7 million of operating cash flow and $5.1 million of free cash flow. U.S. commercial expansion also reached more than 2,100 accounts, with over 400 plastic surgeons trained on Preservé. Third-Quarter 2026 Financial Results
• Neutral Sentiment: Institutional ownership activity was mixed: 117 investors added shares during the latest quarter, while 81 reduced positions. This suggests continued investor interest but no clear consensus. Institutional Ownership Activity
• Negative Sentiment: Adjusted or GAAP loss was $0.35 per share, wider than the consensus loss estimate of $0.26-$0.27, although it improved from a $0.38 loss a year earlier. Higher operating expenses, which rose to $52.3 million from $41.7 million, remain a concern. Establishment Labs Reports Q3 Loss
• Negative Sentiment: Reported insider trading was notably one-sided, with nine sales and no purchases over the past six months, potentially adding to investor caution around the valuation and outlook. Establishment Labs Insider Trading Activity

Analyst Upgrades and Downgrades

Several research firms have recently commented on ESTA. Mizuho upped their price objective on shares of Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a research note on Thursday, August 6th. Needham & Company LLC lifted their price target on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, September 21st. Finally, JPMorgan Chase & Co. raised their price objective on Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.00.

Establishment Labs Price Performance

The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. The stock’s 50-day simple moving average is $67.06 and its two-hundred day simple moving average is $72.34. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of -48.80 and a beta of 1.06.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, October 29th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.09). The company had revenue of $71.99 million during the quarter, compared to analyst estimates of $66.81 million. Establishment Labs had a negative net margin of 14.56% and a negative return on equity of 185.60%. The firm’s revenue for the quarter was up 33.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.38) EPS. Equities research analysts predict that Establishment Labs Holdings Inc. will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

Hedge funds have recently made changes to their positions in the company. State of Wyoming boosted its position in Establishment Labs by 102.1% during the third quarter. State of Wyoming now owns 2,057 shares of the company’s stock worth $132,000 after acquiring an additional 1,039 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Establishment Labs by 220.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,560 shares of the company’s stock valued at $163,000 after acquiring an additional 1,760 shares during the last quarter. Sterling Capital Management LLC raised its holdings in Establishment Labs by 849.5% in the 3rd quarter. Sterling Capital Management LLC now owns 902 shares of the company’s stock valued at $58,000 after acquiring an additional 807 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Establishment Labs in the 3rd quarter valued at about $80,000. Finally, Engineers Gate Manager LP lifted its stake in Establishment Labs by 7.5% in the 2nd quarter. Engineers Gate Manager LP now owns 31,458 shares of the company’s stock worth $2,699,000 after purchasing an additional 2,191 shares in the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.